Compare PHIN & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHIN | HAE |
|---|---|---|
| Founded | 2023 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2023 | 1996 |
| Metric | PHIN | HAE |
|---|---|---|
| Price | $75.71 | $75.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $70.00 | ★ $84.13 |
| AVG Volume (30 Days) | 466.4K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 84.09 | N/A |
| EPS | 0.96 | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $6.35 | N/A |
| Revenue Next Year | $2.29 | $5.23 |
| P/E Ratio | $78.86 | ★ $36.62 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $46.78 | $47.32 |
| 52 Week High | $86.94 | $87.32 |
| Indicator | PHIN | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 58.67 |
| Support Level | $68.81 | $72.04 |
| Resistance Level | $81.04 | $86.72 |
| Average True Range (ATR) | 3.00 | 3.02 |
| MACD | -0.78 | -0.57 |
| Stochastic Oscillator | 14.99 | 34.04 |
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, it generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.